New study aims to tailor breast cancer treatment for patients over 70
NCT ID NCT07273357
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 200 breast cancer patients aged 70 and older who are starting a type of targeted therapy called CDK4/6 inhibitors combined with hormone therapy. The goal is to see how well geriatric screening tools can predict side effects and quality of life changes. Researchers hope to better understand the benefits and risks of this treatment in older adults, who are often underrepresented in clinical trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADJUVANT DRUG THERAPY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Department of Oncology
RECRUITINGGävle, Sweden
-
Department of Oncology
RECRUITINGJönköping, 55312, Sweden
-
Department of Oncology
RECRUITINGKalmar, Sweden
-
Department of Oncology
RECRUITINGLinköping, Sweden
-
Department of Oncology
NOT_YET_RECRUITINGÖrebro, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Exercise during chemo: a new weapon to preserve strength?
- Can a simple checklist predict frailty in older hospital patients?
- Could a smartphone program ease Chemo's emotional toll?
- New drug duo aims to stop aggressive breast cancer's return
- Could fewer heart tests be safer for breast cancer patients?
- New study aims to predict who will respond to breast cancer therapy